Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Should Expand Study Of PBM Business Practices, Senators Say

This article was originally published in The Pink Sheet Daily

Executive Summary

The commission should initiate a second round of data collection focusing on contracts between PBMs and manufacturers, a letter signed by seven senators states. FTC also is urged to collect data on PBM pricing practices for generics.

You may also be interested in...



N.Y. Suit Against Express Scripts Alleges Overcharges For Generic Drugs

The suit focuses on Express Scripts' administration of the New York state employee health plan pharmacy benefit. New York AG alleges that PBM overcharged for generic drugs, "disguised" manufacturer rebates and illegally sold plan data to manufacturers and data collection services.

PBM Conflict Of Interest Study Begins: FTC Contacting 20 PBMs, Pharmacies

The Federal Trade Commission will study whether using a PBM-owned mail order pharmacy costs more than using a non-PBM mail order or retail pharmacy. The study was mandated by the Medicare Rx law.

Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says

The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel